The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Open accessAbstract
The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk in order to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found during the CT-based screening process are the object of the biomarkers described in the present review. We first propose some principles to optimize lung cancer biomarker discovery projects. Then, we summarize the discovery and developmental status of currently promising molecular candidates such as autoantibodies, complement fragments, miRNAs, circulating tumor DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures. We also mention other emerging biomarkers or new technologies to follow such as exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic predisposition studies or the integration of NGS in circulating DNA. We also underline the importance of integrating different molecular technologies together with imaging, radiomics and artificial intelligence. We list a number of completed ongoing or planned trials to show clinical utility of molecular biomarkers. Finally we comment on the future research challenges in the field of biomarkers in the context of lung cancer screening and propose a design of a trial to test clinical utility of one or several biomarker candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Setio, A. A. A., Ciompi, F., Litjens, G., Gerke, P., Jacobs, C., van Riel, S. J., Wille, M. M. W., Naqibullah, M., Sanchez, C. I., & van Ginneken, B. (2016) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2016.2536809 · Cited by 1,258
Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways
Hakim, M., Broza, Y. Y., Barash, O., Peled, N., Phillips, M., Amann, A., & Haick, H. (2012) · Chemical Reviews · doi:10.1021/cr300174a · Cited by 953
Self-citationSupervised Machine Learning for Population Genetics: A New Paradigm
Schrider, D. R., & Kern, A. D. (2018) · Trends in Genetics · doi:10.1016/j.tig.2017.12.005 · Cited by 453
Lee, S. H., Sung, J. Y., Yong, D., Chun, J., Kim, S. Y., Song, J. H., Chung, K. S., Kim, E. Y., Jung, J. Y., Kang, Y. A., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.016 · Cited by 354
Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269
Cited by
Pastorino, U., Silva, M., Sestini, S., Sabia, F., Boeri, M., Cantarutti, A., Sverzellati, N., Sozzi, G., Corrao, G., & Marchianò, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz117 · Cited by 523
Self-citationAdams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01694-4 · Cited by 467
Sakore, P., Bhattacharya, S., Belemkar, S., Prajapati, B. G., & Elossaily, G. M. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2023.101264 · Cited by 64
Artificial Intelligence and its future potential in lung cancer screening
Joy Mathew, C., David, A. M., & Joy Mathew, C. M. (2020) · IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund · doi:10.17179/excli2020-3095 · Cited by 59
Early Diagnosis of Lung Cancer: The Urgent Need of a Clinical Test
Gasparri, R., Guaglio, A., & Spaggiari, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154398 · Cited by 7
Metadata
- Authors
- Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., Mazzone, P. J., & Montuenga, L. M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 14
- Issue
- 3
- Pages
- 343-357
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2903411538
- Cited by
- 539
- References
- 9
- FWCI
- 23.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. https://app.cochat.ai/papers/10.1016/j.jtho.2018.11.023
- The paper
- Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., Mazzone, P. J., & Montuenga, L. M. (2019). Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.11.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
